Current developments, problems and solutions in the non-surgical treatment of pancreatic cancer.

about

Current status and progress of pancreatic cancer in China Pancreatic cancer

P2860

Q26799739-EBB4B94F-C3A3-4AE6-A186-A7251ABF7A0C Q27005724-9C935432-5235-48D9-8D72-FDF88951A6E5

P2860

Current developments, problems and solutions in the non-surgical treatment of pancreatic cancer.

Item

http://www.wikidata.org/entity/Q36733001

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Current developments, problems ...... reatment of pancreatic cancer.

@ast

Current developments, problems ...... reatment of pancreatic cancer.

@en

type

Item

label

Current developments, problems ...... reatment of pancreatic cancer.

@ast

Current developments, problems ...... reatment of pancreatic cancer.

@en

prefLabel

Current developments, problems ...... reatment of pancreatic cancer.

@ast

Current developments, problems ...... reatment of pancreatic cancer.

@en

P1476

Current developments, problems ...... reatment of pancreatic cancer.

@en

P2093

Xiao-Zhong Guo

http://www.w3.org/2001/XMLSchema#string

Xu Liu

http://www.w3.org/2001/XMLSchema#string

Zhong-Min Cui

http://www.w3.org/2001/XMLSchema#string

P2860

Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.

Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial.

Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial.

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.

Heat shock protein 70 inhibits apoptosis in cancer cells through simultaneous and independent mechanisms

Anti-angiogenesis therapy in pancreatic carcinoma.

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.

Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.

Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model

P304

20-28

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.4251/WJGO.V5.I2.20

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236106911

http://www.w3.org/2001/XMLSchema#string

P698

23556053

http://www.w3.org/2001/XMLSchema#string

P932

3613767

http://www.w3.org/2001/XMLSchema#string

Current developments, problems and solutions in the non-surgical treatment of pancreatic cancer.

about

P2860

P2860

Current developments, problems and solutions in the non-surgical treatment of pancreatic cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932